CN102670508A - Stable liposome and preparation method thereof - Google Patents
Stable liposome and preparation method thereof Download PDFInfo
- Publication number
- CN102670508A CN102670508A CN2011100534594A CN201110053459A CN102670508A CN 102670508 A CN102670508 A CN 102670508A CN 2011100534594 A CN2011100534594 A CN 2011100534594A CN 201110053459 A CN201110053459 A CN 201110053459A CN 102670508 A CN102670508 A CN 102670508A
- Authority
- CN
- China
- Prior art keywords
- liposome
- cholesterol
- lecithin
- stabilized liposomes
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a stable liposome and a preparation method thereof. The liposome mainly comprises the following components of phosphatidylcholine, cholesterol, drugs, folic acid and carrier materials, wherein the mass ratio of the phosphatidylcholine, the cholesterol and the drugs is 1-5 : 1 : 0.1; the mass ratio of the folic acid and the drugs is 1 : 3-6; and the mass ratio of the carrier materials and phosphatidylcholine is 3 : 1. The method is simple in process, and is helpful for industrialized production. Particle sizes of the liposome can be effectively controlled by adjusting the ratio of lipid components and by extruding filter. The stability of the liposome can be greatly improved by adding folic acid; and the liposome with small and homogeneous particle sizes and with good stability can be obtained, so that the application value of the liposome is greatly increased. An effect of moistening skins for a long time can be achieved via a transdermal delivery in a liposome way by using allocatechin gallate liposome prepared by the method of the invention.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of stabilized liposomes and preparation method thereof.
Background technology
Liposome is the self-assembly of lipid molecule (lipoid), is a kind of by the structure that coats little water in the middle of one or more double-layers of lipoid.In the forming process of liposome, the film forming surfaces externally and internally layer of hydrophilic head shape, and oil loving afterbody is in the centre of film, wall thickness is about 5-7nm, and the diameter of capsule is generally between 25-500nm.This structure of liposome makes it can carry various hydrophilic, hydrophobic or amphipathic materials, and these materials are wrapped into the liposome interior water, or inserts a type lipid bilayer, or absorption is attached at the surface of liposome.
Medicine is processed liposome have following characteristics afterwards: 1. improved the availability of medicine, reduced dosage.2. strengthen the targeting property of medicine.3. has slow-release function.
The envelop rate of liposome, stability and particle diameter are most important 3 parts.It is not very difficult obtaining high envelop rate liposome as long as method for preparing is selected suitable; But want liposome in aqueous solution and body follow, to keep good stable property; Then not only require liposome that lower percolation ratio is arranged; Thereby more even and little particle diameter also will have surface of good stability to engulf the extension body circulation time with what hide mononuclear phagocyte system in the body, to reach the best use of.
In sum, because the characteristics and the superperformance of liposome, if can solve above-mentioned problem, utilization is stablized feasible method for preparing lipidosome and is obtained effective Liposomal formulation.
Summary of the invention
The objective of the invention is to overcome the problem of liposome and medicine stability, a kind of stabilized liposomes is provided.
Another object of the present invention is to provide a kind of method for preparing of stabilized liposomes.
The object of the invention can be realized through following technical scheme:
A kind of stabilized liposomes; It is mainly composed of the following components: lecithin, cholesterol, medicine, folic acid and carrier mass; Wherein the mass ratio of lecithin, cholesterol and medicine is 1～5: 1: 0.1; The mass ratio of folic acid and medicine is 1: 3～6, and the mass ratio of carrier mass and lecithin is 3: 1.
Above-mentioned stabilized liposomes, its described lecithin is hydrogenated soy phosphatidyl choline, soybean lecithin or Ovum Gallus domesticus Flavus lecithin; Described cholesterol is protein cholesterol, serum cholesterol, yolk cholesterol or gallbladder cholesterol; Described carrier mass is trehalose, lactose or mannitol; Described medicine is nutgall catechin gallic acid ester or epigallocatechin gallate (EGCG).
Above-mentioned stabilized liposomes also contains antioxidant in its described liposome, and wherein antioxidant and principal agent ratio are 1～3: 50.Described antioxidant is a vitamin E.
The method for preparing of above-mentioned stabilized liposomes may further comprise the steps:
(1) be 1～5 with lecithin, cholesterol and medicine in mass ratio: 1: 0.1 ratio is dissolved in and obtains solution A in the organic solvent, and wherein the mass volume ratio of lecithin and organic solvent is 1: 4～10 (g/ml); With folic acid be dissolved in the dimethyl sulfoxine solution B, wherein 1mg folic acid needs the dissolving of 10 μ l dimethyl sulfoxines, the mass ratio of folic acid and medicine is 1: 3～6; Solution A, B are mixed and add carrier mass get mixture C, the mass ratio of carrier mass and lecithin is 3: 1, this solution C is removed organic solvent obtain immobilized artificial membrane;
(2) step (1) gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, this liposome is filtered with squeezing and pressing method, obtain liposome solutions through high pressure homogenization method;
(3) the liposome solutions lyophilization that step (2) is obtained removes desolvates, and obtains freeze dried liposome.
The used microporous filter membrane aperture of squeezing and pressing method filtration is 0.2 μ m in the method for preparing of above-mentioned stabilized liposomes, its step (2); The concrete technology of high pressure homogenization method is: solution is added adopt circulation step by step to boost in the homogenizer, pressure limit is 200-1000Mpa.
The method for preparing of above-mentioned stabilized liposomes, it is that described lecithin is hydrogenated soy phosphatidyl choline, soybean lecithin or Ovum Gallus domesticus Flavus lecithin; Described cholesterol is protein cholesterol, serum cholesterol, yolk cholesterol or gallbladder cholesterol; Described carrier mass is trehalose, lactose or mannitol; Described medicine is nutgall catechin gallic acid ester or epigallocatechin gallate (EGCG).
The method for preparing of above-mentioned stabilized liposomes, its described organic solvent are any one or two kinds in dehydrated alcohol and the chloroform.
The method for preparing of above-mentioned stabilized liposomes, it is also to add antioxidant in step (1) the gained solution A, and antioxidant and principal agent ratio are 1～3: 50.Described antioxidant is: vitamin E.
The present invention has added folic acid, and folic acid is needed by human body nutritional labeling still not, and significantly increases the stability of liposome, has enlarged the range of application of liposome.Folic acid and principal agent ratio are 1: 3～6.The present invention directly is attached to the carrier mass surface with immobilized artificial membrane in film forming process, because carrier mass has very little particle diameter (crossing 200 mesh sieves), so immobilized artificial membrane itself just can form the very liposome of small particle diameter in the process of aquation.In that to add that press filtration and high pressure homogenization technique maintain the particle diameter of liposome very narrow than small scale and particle size range.Folic acid can embed in the liposome duplicature in the process of preparation, thereby significantly increases the stability of liposome membrane, thereby reduces percolation ratio.
Beneficial effect of the present invention:
The present invention has added folic acid, and folic acid is needed by human body nutritional labeling still not, and significantly increases the stability of liposome, has enlarged the range of application of liposome.
The inventive method technology is very simple, and be very easy to amplify, help suitability for industrialized production.The inventive method has found the method for a kind of effective control liposome particle diameter and stability.The inventive method through high pressure homogenizer its homogenization pressure of adjustment and press filtration, can effectively be controlled the particle diameter of liposome through the adding (add folic acid, play the effect of stabilized liposome film) of adjustment proportion between lipid components and folic acid.Owing to can accomplish homogeneous grain diameter, the granular liposome of good stability has increased using value of the present invention greatly.
Involved solvent is a dehydrated alcohol among the present invention, and the dimethyl sulfoxine of chloroform and trace can be crossed on Rotary Evaporators comparatively completely and to remove, so that the product that finally obtains has hardly is residual.
Nutgall catechin gallic acid ester liposome through the inventive method preparation carries out the effect that transdermal administration then can reach long-term skin care with the liposome mode.
The specific embodiment
The preparation of embodiment 1 nutgall catechin gallic acid ester liposome
Is that the ratio of 3g: 1g: 0.1g is dissolved in dehydrated alcohol and chloroform (volume ratio of dehydrated alcohol and chloroform is 1: 1 with lecithin and cholesterol and nutgall catechin gallic acid ester in quality; Cumulative volume is 15ml) mixed solution in and add vitamin E2 mg and obtain solution A; With an amount of folic acid 33mg be dissolved in the 330 μ l dimethyl sulfoxines solution B; Solution A, B are mixed and add the 9g lactose get mixture C, this solution C is obtained immobilized artificial membrane except that desolvating; The gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, with this liposome through 0.2 μ m membrane filtration, with liposome solutions in high pressure homogenizer under pressure 200-400Mpa supercharging homogenizing 2h step by step, the liposome that obtains is the solution of clear and bright homogeneous.The liposome solutions lyophilization that obtains except that desolvating, is obtained freeze dried nutgall catechin gallic acid ester liposome.Freeze dried nutgall catechin gallic acid ester liposome powder is added distilled water jolting dissolving, and measure particle diameter with Ls-230 type laser light scattering particle size analyzer (U.S. Beckman Coulter company).The particle diameter of liposome is respectively 90.8nm ± 5.2nm (n=3).With sem observation gained liposome.Under ultramicroscope, observing liposome is ball, and result big or small and with particle size analyzer determination matches.Using ultrafiltration to measure liposome encapsulation is 90.3%, and the 48h percolation ratio is 1.2%.
The preparation of embodiment 2 epigallocatechin gallate (EGCG) liposomees
Is that the ratio of 5g: 1g: 0.1g is dissolved in dehydrated alcohol and chloroform (volume ratio of dehydrated alcohol and chloroform is 1: 1 with lecithin and cholesterol and epigallocatechin gallate (EGCG) liposome in mass ratio; Cumulative volume is 25ml) mixed solution and add vitamin E 4mg and obtain solution A; With an amount of folic acid 20mg be dissolved in the 200 μ l dimethyl sulfoxines solution B; Solution A, B mixed and add an amount of 15g mannitol getting mixture C, this solution C is removed to desolvate obtain immobilized artificial membrane; The gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, with this liposome through 0.2 μ m membrane filtration, with liposome solutions in high pressure homogenizer under pressure 400-800Mpa supercharging homogenizing 2h step by step, the liposome that obtains is the solution of clear and bright homogeneous.The liposome solutions lyophilization that obtains except that desolvating, is obtained freeze dried epigallocatechin gallate (EGCG) liposome.Freeze dried epigallocatechin gallate (EGCG) liposome powder is added distilled water jolting dissolving, and measure particle diameter.The particle diameter of liposome is respectively 93.5nm ± 3.4nm (n=3).Using ultrafiltration to measure liposome encapsulation is 91.5%, and the 48h percolation ratio is 2.3%.
The preparation of embodiment 3 nutgall catechin gallic acid ester liposomees
Is that the ratio of 2g: 1g: 0.1g is dissolved in dehydrated alcohol and chloroform (volume ratio of dehydrated alcohol and chloroform is 1: 1 with lecithin and cholesterol and medicine in mass ratio; Cumulative volume is 10ml) mixed solution and add vitamin E 6mg and obtain solution A; With an amount of folic acid 17mg be dissolved in the 170 μ l dimethyl sulfoxines solution B; Solution A, B mixed and add an amount of 6g trehalose getting mixture C, this solution C is removed to desolvate obtain immobilized artificial membrane; The gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, with this liposome through 0.2 μ m membrane filtration, with liposome solutions in high pressure homogenizer under pressure 400-1000Mpa supercharging homogenizing 2h step by step, the liposome that obtains is the solution of clear and bright homogeneous.The liposome solutions lyophilization that obtains except that desolvating, is obtained freeze dried nutgall catechin gallic acid ester liposome.Freeze dried nutgall catechin gallic acid ester liposome powder is added distilled water jolting dissolving, and measure particle diameter.The particle diameter of liposome is respectively 87.6nm ± 4.4nm (n=3).Using ultrafiltration to measure liposome encapsulation is 88.5%, and the 48h percolation ratio is 3.1%.
Freeze dried nutgall catechin gallic acid ester liposome powder is carried out the configuration of skin-nourishing liquid by following prescription:
The 5g freeze-dried powder is become the homogeneous transparent liposome solutions with the 90ml deionized water dissolving, add 5g propylene glycol and alcoholic acid mixed solution, add an amount of spice and get liposome skin-nourishing liquid.Performance test is following:
(1) pH scope: 6-8;
(2) stability :-12 ℃ of storages were stored no layering in 24 hours and deposited phenomenon in 24 hours and 40 ℃;
(3) sense organ and the sense of taste: fine and smooth, lubricate, have no irritating odor;
(4) get refrigerated Fructus Foeniculi pig ear skin (approaching) and place normal saline to thaw, clean with application on human skin.Its skin surface is fixed on (the full-automatic body outer osmotic analyzer of U.S. Hanson, diffusion cell nozzle diameter D=1.50cm, cross-sectional area S=1.767cm in the receiving chamber of diffusion cell towards the donor chamber
2), draining bubble, precision is measured 1ml liposome skin-nourishing liquid on the keratodermatitis of donor chamber.Recirculated water keeps 37 ℃ ± 0.5 ℃.Acceptable solution is 30% alcoholic acid normal saline (the acceptable solution volume is 7.0ml in the receiving chamber), adds the speed stirring of stirrer with 200r/min, operates 12 parts altogether; Be divided into four groups, 3 parts every group, respectively at 0.5; 1,3,24h gets skin layer; Measure skin layer Chinese medicine content after treatment, compare, measure the percentage ratio of skin Chinese medicine with adding dose.The result is following:
Can know by the result, the entering skin layer that liposome can be very fast, and can be detained the long period at skin layer, thus reach long-acting.Bibliographical information; Can have medication amount that more serious destruction causes actual absorption seldom at gastrointestinal tract after nutgall catechin gallic acid ester is oral; The amount that can reach skin is then still less carried out the effect that transdermal administration then can reach long-term skin care with the liposome mode.
Comparative example 1
Prepare the nutgall catechin gallic acid ester conventional liposome as follows; Is that the ratio of 2g: 1g: 0.1g is dissolved in dehydrated alcohol and chloroform (volume ratio of dehydrated alcohol and chloroform is 1: 1 with lecithin and cholesterol and medicine in mass ratio; Cumulative volume is 10ml) mixed solution in obtain solution A, this solution A removed to desolvate obtain immobilized artificial membrane; The gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, with this liposome through 0.2 μ m membrane filtration, with liposome solutions in high pressure homogenizer under pressure 400-1000Mpa supercharging homogenizing 2h step by step, obtain liposome solutions.The liposome solutions that obtains is added the 6g trehalose as freeze drying protectant, and lyophilization removes and desolvates, and obtains freeze dried nutgall catechin gallic acid ester conventional liposome.Freeze-dried powder is added distilled water jolting dissolving, and measure particle diameter.The particle diameter of liposome is respectively 110.3nm ± 23.4nm (n=3).Using ultrafiltration to measure liposome encapsulation is 76.9%, and the 48h percolation ratio is 22.1%.Prepare conventional liposome skin-nourishing liquid by identical method, the result is following with the method transdermal experiment:
The result is visible, and not only transit dose is few for the nutgall catechin gallic acid ester liposome of prior art for preparing, and the time that in skin, keeps is short.
Claims (10)
1. stabilized liposomes; It is characterized in that mainly composed of the following components: lecithin, cholesterol, medicine, folic acid and carrier mass; Wherein the mass ratio of lecithin, cholesterol and medicine is 1～5: 1: 0.1; The mass ratio of folic acid and medicine is 1: 3～6, and the mass ratio of carrier mass and lecithin is 3: 1.
2. stabilized liposomes according to claim 1 is characterized in that described lecithin is hydrogenated soy phosphatidyl choline, soybean lecithin or Ovum Gallus domesticus Flavus lecithin; Described cholesterol is protein cholesterol, serum cholesterol, yolk cholesterol or gallbladder cholesterol; Described carrier mass is trehalose, lactose or mannitol; Described medicine is nutgall catechin gallic acid ester or epigallocatechin gallate (EGCG).
3. stabilized liposomes according to claim 1 is characterized in that also containing in the described liposome antioxidant, and wherein antioxidant and principal agent ratio are 1～3: 50.
4. stabilized liposomes according to claim 3 is characterized in that described antioxidant is a vitamin E.
5. the method for preparing of the described stabilized liposomes of claim 1 is characterized in that may further comprise the steps:
(1) be 1～5 with lecithin, cholesterol and medicine in mass ratio: 1: 0.1 ratio is dissolved in and obtains solution A in the organic solvent, and wherein the mass volume ratio of lecithin and organic solvent is 1: 4～10; With folic acid be dissolved in the dimethyl sulfoxine solution B, wherein 1mg folic acid needs the dissolving of 10 μ l dimethyl sulfoxines, the mass ratio of folic acid and medicine is 1: 3～6; Solution A, B are mixed and add carrier mass get mixture C, the mass ratio of carrier mass and lecithin is 3: 1, this solution C is removed organic solvent obtain immobilized artificial membrane;
(2) step (1) gained immobilized artificial membrane is water-soluble, after aquation, obtain liposome, this liposome is filtered with squeezing and pressing method, obtain liposome solutions through high pressure homogenization method;
(3) the liposome solutions lyophilization that step (2) is obtained removes desolvates, and obtains freeze dried liposome.
6. the method for preparing of stabilized liposomes according to claim 1 is characterized in that the used microporous filter membrane aperture of squeezing and pressing method filtration is 0.2 μ m in the step (2); The concrete technology of high pressure homogenization method is: solution is added adopt circulation step by step to boost in the homogenizer, pressure limit is 200-1000Mpa.
7. the method for preparing of stabilized liposomes according to claim 5 is characterized in that described lecithin is hydrogenated soy phosphatidyl choline, soybean lecithin or Ovum Gallus domesticus Flavus lecithin; Described cholesterol is protein cholesterol, serum cholesterol, yolk cholesterol or gallbladder cholesterol; Described carrier mass is trehalose, lactose or mannitol; Described medicine is nutgall catechin gallic acid ester or epigallocatechin gallate (EGCG).
8. the method for preparing of stabilized liposomes according to claim 5 is characterized in that described organic solvent is any one or two kinds in dehydrated alcohol and the chloroform.
9. the method for preparing of stabilized liposomes according to claim 5 is characterized in that also adding antioxidant in step (1) the gained solution A, and antioxidant and principal agent ratio are 1～3: 50.
10. the method for preparing of stabilized liposomes according to claim 9 is characterized in that described antioxidant is: vitamin E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110053459.4A CN102670508B (en) | 2011-03-07 | 2011-03-07 | A kind of stable liposome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110053459.4A CN102670508B (en) | 2011-03-07 | 2011-03-07 | A kind of stable liposome and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102670508A true CN102670508A (en) | 2012-09-19 |
| CN102670508B CN102670508B (en) | 2015-10-28 |
Family
ID=46803506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110053459.4A Active CN102670508B (en) | 2011-03-07 | 2011-03-07 | A kind of stable liposome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670508B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536589A (en) * | 2013-09-30 | 2014-01-29 | 中国计量学院 | Preparation method of compound nano lipidosome capable of improving bioavailability of catechinic acid |
| CN103610642A (en) * | 2013-12-10 | 2014-03-05 | 中国计量学院 | Lipidosome encapsulating epigallocatechin gallate and preparation method thereof |
| US20150313824A1 (en) * | 2013-01-28 | 2015-11-05 | Conopco, Inc., D/B/A Unilever | Skin care composition |
| CN105456193A (en) * | 2015-12-15 | 2016-04-06 | 江南大学 | EGCC liposome preparation and preparation method thereof |
| CN107432875A (en) * | 2017-09-05 | 2017-12-05 | 石河子大学 | It is a kind of to be used to treat functional motor ability plastid of lung neoplasm and preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632675A (en) * | 2009-08-14 | 2010-01-27 | 海南永田药物研究院有限公司 | Ferrous fumarate and folic acid pharmaceutical composition and liposome solid preparation thereof |
-
2011
- 2011-03-07 CN CN201110053459.4A patent/CN102670508B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101632675A (en) * | 2009-08-14 | 2010-01-27 | 海南永田药物研究院有限公司 | Ferrous fumarate and folic acid pharmaceutical composition and liposome solid preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 徐晶等: "不同剂型表没食子儿茶素没食子酸酯对中波紫外线辐射后BALB/C小鼠表皮细胞凋亡的影响", 《中国药学杂志》, vol. 42, no. 20, 31 October 2007 (2007-10-31) * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150313824A1 (en) * | 2013-01-28 | 2015-11-05 | Conopco, Inc., D/B/A Unilever | Skin care composition |
| CN105431131A (en) * | 2013-01-28 | 2016-03-23 | 荷兰联合利华有限公司 | Skin care composition |
| JP2016514085A (en) * | 2013-01-28 | 2016-05-19 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Skin care composition |
| CN103536589A (en) * | 2013-09-30 | 2014-01-29 | 中国计量学院 | Preparation method of compound nano lipidosome capable of improving bioavailability of catechinic acid |
| CN103536589B (en) * | 2013-09-30 | 2015-09-23 | 中国计量学院 | The preparation method of the compound recipe nanometer liposome of catechin bioavailability can be improved |
| CN103610642A (en) * | 2013-12-10 | 2014-03-05 | 中国计量学院 | Lipidosome encapsulating epigallocatechin gallate and preparation method thereof |
| CN103610642B (en) * | 2013-12-10 | 2016-05-04 | 中国计量学院 | A kind of liposome and preparation method who seals Epigallo-catechin gallate (EGCG) |
| CN105456193A (en) * | 2015-12-15 | 2016-04-06 | 江南大学 | EGCC liposome preparation and preparation method thereof |
| CN107432875A (en) * | 2017-09-05 | 2017-12-05 | 石河子大学 | It is a kind of to be used to treat functional motor ability plastid of lung neoplasm and preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102670508B (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Enhanced oral bioavailability of capsaicin in mixed polymeric micelles: Preparation, in vitro and in vivo evaluation | |
| Agrawal et al. | Development and evaluation of curcumin-loaded elastic vesicles as an effective topical anti-inflammatory formulation | |
| CN102397168B (en) | Flexible nanoliposomes with charges for cosmetics and preparation method thereof | |
| CN103494773B (en) | A kind of ZL006 liposome and preparation method thereof | |
| CN103520006A (en) | Flexible nano liposome as well as preparation method and application of flexible nano liposome | |
| CN102670508B (en) | A kind of stable liposome and preparation method thereof | |
| CN103520007A (en) | Skin active factor flexible nano-liposome and preparation method and application thereof | |
| Wichayapreechar et al. | Dermal targeting of Centella asiatica extract using hyaluronic acid surface modified niosomes | |
| Yong-Tai et al. | Solid lipid nanoparticles formulated for transdermal aconitine administration and evaluated in vitro and in vivo | |
| Xia et al. | In vitro evaluation of α-lipoic acid-loaded lipid nanocapsules for topical delivery | |
| CN113975234A (en) | Hydroxyl-alpha-sanshool nano liposome and preparation method thereof | |
| US20170049701A1 (en) | Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients | |
| JP7390738B2 (en) | Nanocapsules coated with chitosan and their uses | |
| Wu et al. | Cholesterol and phospholipid-free multilamellar niosomes regulate transdermal permeation of a hydrophobic agent potentially administrated for treating diseases in deep hair follicles | |
| Wang et al. | FK506-loaded solid lipid nanoparticles: preparation, characterization and in vitro transdermal drug delivery | |
| CN116350590A (en) | Production and filtration process of honokiol liposome | |
| Liu et al. | Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes | |
| EP3138555A1 (en) | Liposome composition and production method therefor | |
| Venugopal et al. | Formulation development and characterization of tea tree oil loaded ethosomes | |
| CN114099438A (en) | Kaempferol liposome gel and preparation method thereof | |
| Khalil et al. | Novel dermal nanobilosomes with promising browning effect of adipose tissue for management of obesity | |
| CN106389336B (en) | Liquid crystal nanoparticle precursor particles, self assembly liquid crystal nanoparticle and preparation method thereof | |
| Chu et al. | Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo | |
| CN101804028A (en) | Method for preparing traditional Chinese medicine liposome | |
| Bhinge et al. | Herbal liposomes: natural network for targeted drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |